Quick Answer
Nurix Therapeutics, Inc. reported Revenue (ASC 606) of $83.98 million for fiscal year 2025.
Nurix Therapeutics, Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $83.98M | +54.0% |
| 2024 | $54.55M | -29.1% |
| 2023 | $76.99M | +99.3% |
| 2022 | $38.63M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| August 31, 2025 | $7.89M | -37.3% | -82.1% |
| May 31, 2025 | $44.06M | +264.3% | +138.7% |
| February 28, 2025 | $18.45M | +11.3% | +46.6% |
| August 31, 2024 | $12.59M | -31.8% | +4.1% |
| May 31, 2024 | $12.09M | -60.6% | -27.1% |
| February 29, 2024 | $16.59M | — | -10.2% |
| August 31, 2023 | $18.47M | — | -39.8% |
| May 31, 2023 | $30.68M | — | — |
- Nurix Therapeutics, Inc. showed an increase of +54.0% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2022–2025 period, Nurix Therapeutics, Inc.’s revenue (asc 606) has grown by 117.4% (from $38.63 million to $83.98 million).
- The most recent figure is from Nurix Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on January 28, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: